skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

The world’s political tectonic plates may be shifting, but this has done little to undermine the achievements of the pharma, biotech and allied industries over the past year, and last night we celebrated the best of these at the 12th annual Scrip Awards in London. 

 

In a lavish ceremony presented by the broadcaster Jeremy Vine, most recently seen walking all over the BBC’s US election night virtual map, Scrip rewarded excellence across the whole range of business activities between June 2015 and May 2016.

 

 

2016 has proved to be an interesting year in many unexpected ways, creating uncertainty for our sector. But against a changing political backdrop, industry has continued to develop innovative new drugs, make strides in scientific research and forge new alliances. New investment continues to flow into biotech even as we grapple with pricing and the coming of age of biosimilars.

The Scrip Awards categories range from those that reward the broader achievements of companies, to those for innovation in deal making, advances in R&D and the more personal accomplishments of teams and individuals. New this year, we added the Community Partnership of the Year award to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community.

Overall, Genmab was the big winner of the night, receiving two trophies, but the loudest applause went to this year’s Lifetime Achievement Award recipient, Dr. Raymond F. Schinazi.

 

 

See the full list of the 2016 Scrip Awards winners herehttp://www.scripawards.com/2016-winners/

Read also

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    By Brian Yang

    <span style="color: #58595b; text-align: start; letter-spacing: normal;">Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.</span>

    Topics Policy and regulation

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: